source
- Epicrispr secures $90M Series C to advance epigenetic therapy for rare muscle diseaseEpicrispr Biotechnologies announced a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, with participation from Sanofi Ventures and other investors. The c…
- Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves aheadAurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…